The earnings miss is immaterial for a pre-revenue biotech, the stock will trade on the VIKTORIA-1 data readout and the July 17 PDUFA date. Monitor ASCO 2026 presentation on June 2 for detailed efficacy/safety data, which could further derisk the sNDA path. The expanded VIKTORIA-2 study adds first-line optionality, extending the addressable market.
CELC drugs
CELC drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $137.68entry
- T+1 · 6mo ago −3.99%α −3.93% · $132.18
- T+5 · 6mo ago +0.40%α −0.56% · $138.23
- T+20 · 5mo ago −35.91%α −38.03% · $88.24
- T+60 · 3mo ago −36.00%α −40.52% · $88.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity reported Q1 2026 GAAP EPS of -$0.97, a 9.0% miss vs consensus of -$0.89, with net loss widening to $52.8M from $37.0M a year ago. The key catalyst is the positive Phase 3 VIKTORIA-1 topline data in the PIK3CA mutant cohort, supporting an sNDA submission in Q3 2026 ahead of the July 17 PDUFA date for the wild-type NDA. The stock's move will be driven by the clinical progress and regulatory timeline, not the earnings miss, as the company remains pre-revenue.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.97 vs consensus -$0.89 (9.0% miss); net loss $52.8M vs $37.0M YoY
- Phase 3 VIKTORIA-1 PIK3CA mutant cohort met primary endpoint with statistically significant PFS improvement vs alpelisib
- FDA Priority Review for gedatolisib NDA in PIK3CA wild-type ABC; PDUFA date July 17, 2026
- sNDA submission for PIK3CA mutant cohort planned for Q3 2026
- Cash, equivalents, and investments of $387.1M expected to fund operations through 2027
- VIKTORIA-2 expanded to include Study 2 evaluating gedatolisib as first-line treatment in endocrine-sensitive HR+/HER2- ABC
Financial Impact
Net loss widened by $15.8M YoY to $52.8M; operating expenses increased 40% to $50.5M driven by commercial launch preparation
Risk Factors
- FDA could issue a Complete Response Letter (CRL) on July 17, delaying or denying approval
- Commercial launch costs will accelerate cash burn; need for additional financing before 2027
- Competitive landscape includes Novartis's Piqray and other PI3K/AKT/mTOR inhibitors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295313 |
Track record
26 reports on CELC
6 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers